1GLOBAL
1GLOBAL, a top-tier mobile virtual network operator (MVNO) today announced a strategic partnership with Verint to transform compliance across the financial services and trading sectors to upgrade mobile compliance recording solutions for financial institutions throughout the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711072434/en/
1GLOBAL and Verint partner to offer enhanced Mobile Compliance Recording worldwide (Graphic: Business Wire)
Through this new alliance, 1GLOBAL will now provide all of its global clients with trusted cloud-based recording solutions supported by Verint Financial Compliance. Professionals with compliance obligations can increase their productivity and further their capabilities with voice transcription featuring keyword searching, alerting and meeting summaries.
1GLOBAL clients will also be able to reliably conform with compliance and trade surveillance policies under MiFID II, Dodd-Frank, and MAR / MAD II (among others) to help avoid non-compliance fines and penalties. This new toolset will accelerate compliance audits and easily provide regulatory agencies with complete records of trade-related interactions in a timely manner. Building in these efficiencies reduces costs for financial organizations by leveraging simplified administration, streamlined conversation retrieval, automated rules, and a wide set of external storage integrations on one single contract.
"Partnering with Verint enables us to offer our customers access to the most innovative cloud-based recording solutions on the market,” said Siobhan Thompson, Head of 1GLOBAL Compliance. “Compliance in the cloud is key to 1GLOBAL's strategy. Our partnership with Verint and their VFC platform for our cloud hosting is a testament to that. Verint's cutting edge technology coupled with 1GLOBAL's leading mobile recording capabilities provides customers with assured compliance capabilities as well as increased productivity and analytics.”
“Combining the 1GLOBAL mobile voice and SMS capture capability with the core Verint solution is a critical part of the joint strategy to align all communications into a user-centric view,” says Verint’s John Bourne, Senior VP Global Channels & Alliances. “The integration will provide customers with more control, increased data completeness and the ability to proactively expose compliance anomalies.”
More information on 1GLOBAL’s compliance solution can be found at https://www.1global.com/compliance
About 1GLOBAL
1GLOBAL are market leaders in digital transformation, offering a comprehensive suite of products engineered to facilitate global connectivity at any scale. From truly borderless global business roaming to financial compliance and recording, each solution represents a commitment to excellence.
Started in 2022 by Hakan Koç, co-founder and former co-CEO of AUTO1 Group, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and are a fully regulated MVNO in nine of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711072434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom